Finerenone in Patients with Nondiabetic Chronic Kidney Disease—A Retrospective Study

<b>Background & Objectives:</b> Data on the efficacy and adverse effects of finerenone in patients with nondiabetic chronic kidney disease (CKD) are limited, particularly regarding ethnic diversity. This study aimed to evaluate the outcomes of finerenone in patients with nondiabetic CKD previously treated with standard therapies and investigate associated adverse effects, including hyperkalemia and hypotension. <b>Methods:</b> This is a retrospective exploratory study. It is a single-center study including patients with nondiabetic CKD who visited King Fahad Medical City in Riyadh, Saudi Arabia. The primary exposure was finerenone treatment, assessing its effects on albuminuria, kidney function, and blood pressure (BP), following prior use of renin-angiotensin-aldosterone system and sodium-glucose transport protein 2 inhibitors. The measured outcomes were the urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR). The UACR (primary endpoint) was calculated as the mean of two morning spot urine samples collected consecutively 1 day apart. During each 4-week treatment period, secondary endpoints included changes in UACR, as determined by a 24 h urine sample, BP, and eGFR. The Wilcoxon signed-rank test was used to compare changes in continuous variables before and after therapy initiation. Statistical significance was set at <i>p</i> < 0.05. <b>Results:</b> This study included 16 patients with nondiabetic CKD (median age, 38.5 years [range, 35-50 years]; 56.3% male). The baseline eGFR was 66 mL/min/1.73 m² (47-82.5), with a UACR of 90.0 mg/g (58.8-132.5). No hyperkalemia was observed (potassium level, 4 mmol/L [3.8-4.4]). However, significant reductions in systolic and diastolic BPs were observed. Albuminuria improved significantly: the UACR decreased from 90.0 to 39.3 mg/g (<i>p</i> = 0.04). No adverse events, including hyperkalemia or hypotension, were reported. <b>Conclusions:</b> Finerenone showed promise in reducing albuminuria and blood pressure among patients with nondiabetic chronic kidney disease, with no significant adverse effects reported. These findings suggest potential benefits for this patient population, warranting further investigation.